savolitinib
Selected indexed studies
- Savolitinib: First Approval. (Drugs, 2021) [PMID:34455538]
- Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study. (Lancet Respir Med, 2024) [PMID:39270695]
- Savolitinib: A Promising Targeting Agent for Cancer. (Cancers (Basel), 2023) [PMID:37835402]
_Worker-drafted node — pending editorial review._
Connections
savolitinib is a side effect of
Sources
- Savolitinib: First Approval. (2021) pubmed
- Savolitinib in patients in China with locally advanced or metastatic treatment-naive non-small-cell lung cancer harbouring MET exon 14 skipping mutations: results from a single-arm, multicohort, multicentre, open-label, phase 3b confirmatory study. (2024) pubmed
- Savolitinib: A Promising Targeting Agent for Cancer. (2023) pubmed
- Savolitinib plus osimertinib in epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer with MET overexpression and/or amplification following disease progression on osimertinib: primary results from the phase II SAVANNAH study. (2025) pubmed
- A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial. (2021) pubmed
- TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer. (2020) pubmed
- Savolitinib plus osimertinib versus chemotherapy for advanced, EGFR mutation-positive, MET-amplified non-small-cell lung cancer in China (SACHI): interim analysis of a multicentre, open-label, phase 3 randomised controlled trial. (2026) pubmed
- Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor-Mutated, MET-Amplified Non-Small Cell Lung Cancer: TATTON. (2023) pubmed
- Landscape of Savolitinib Development for the Treatment of Non-Small Cell Lung Cancer with MET Alteration-A Narrative Review. (2022) pubmed
- Savolitinib for non-small cell lung cancer. (2023) pubmed